Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Antzeko izenburuak

• Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
  nork: Tanaka, Yoshiya, et al.
  Argitaratua: (2019)
• Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
  nork: Yoshiya Tanaka, et al.
  Argitaratua: (2019-04-01)
• Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
  nork: Strand, Vibeke, et al.
  Argitaratua: (2016)
• Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
  nork: Genovese, Mark C, et al.
  Argitaratua: (2019)
• Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
  nork: Boyapati, Anita, et al.
  Argitaratua: (2016)